Medicinal – Page 24

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder

mycolabadmin

Researchers tested whether psilocybin mushrooms could help treat obsessive-compulsive disorder (OCD) using mice. They found that psilocybin reduced compulsive burying behavior in mice, similar to how approved OCD medications work. The study revealed that this anti-compulsive effect works through different brain mechanisms than previously thought, and that combining psilocybin with another drug called buspirone might block psychedelic effects while keeping therapeutic benefits.

Chaga mushroom triterpenoids as adjuncts to minimally invasive cancer therapies: A review

mycolabadmin

Chaga mushroom, a fungus that grows on birch trees, contains special compounds called triterpenoids that can kill cancer cells in laboratory tests. Some of these compounds, particularly inotodiol and betulinic acid, show anti-cancer activity similar to or better than conventional chemotherapy drugs. While promising, researchers need to improve how these compounds are absorbed in the body and test them more thoroughly in animals and humans before they can be used clinically.

Prebiotics and Probiotics Supplementation in Pigs as a Model for Human Gut Health and Disease

mycolabadmin

Pigs are excellent models for studying human digestive health because their gut anatomy and function closely resemble humans. This review shows that prebiotics (special food compounds) and probiotics (beneficial bacteria) can improve gut health and strengthen the intestinal barrier in both healthy pigs and those with infections. These findings suggest that similar treatments might help prevent and treat digestive diseases in humans.

Group psychedelic therapy: empirical estimates of cost-savings and improved access

mycolabadmin

This study examines whether treating multiple patients together in psychedelic-assisted therapy sessions could reduce costs and help more people access these promising psychiatric treatments. Researchers compared group versus individual therapy using MDMA for PTSD and psilocybin for depression, finding that group therapy saved about 35-51% on clinician costs. If adopted widely, group therapy could reduce the number of clinicians needed and potentially save billions of dollars while helping thousands more patients receive treatment.

Biodiversity and biological applications of marine actinomycetes—Abu-Qir Bay, Mediterranean Sea, Egypt

mycolabadmin

Researchers isolated bacteria called actinomycetes from the Mediterranean Sea in Egypt that naturally produce colorful pigments. They found that one specific bacterium (Streptomyces tunisiensis) produces a green pigment with promising anti-inflammatory properties similar to common pain relievers. By optimizing the growth conditions, the scientists increased pigment production by over 12 times, suggesting potential applications in medicine and industry.

Leveraging polysaccharide-derived nanocarriers to open new horizons in oral vaccine activation

mycolabadmin

Oral vaccines are easier to administer than injections, but the stomach’s harsh environment destroys them before they work. Scientists are developing special nanocarrier particles made from natural plant materials, especially those used in traditional Chinese medicine, that protect vaccine ingredients and trigger stronger immune responses in the gut. These carriers work like protective vehicles that deliver vaccines safely to immune cells in the intestines, potentially revolutionizing how we vaccinate people worldwide.

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

mycolabadmin

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

Research Topic: Medicinal